

Tatiana Tilli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2927062/publications.pdf>

Version: 2024-02-01

29
papers

676
citations

623734

14
h-index

610901

24
g-index

29
all docs

29
docs citations

29
times ranked

871
citing authors

#	ARTICLE	IF	CITATIONS
1	Biotechnological Evolution of siRNA Molecules: From Bench Tool to the Refined Drug. <i>Pharmaceuticals</i> , 2022, 15, 575.	3.8	11
2	Fibromodulin Gene Variants (FMOD) as Potential Biomarkers for Prostate Cancer and Benign Prostatic Hyperplasia. <i>Disease Markers</i> , 2022, 2022, 1-8.	1.3	3
3	Pieces of the Complex Puzzle of Cancer Cell Energy Metabolism: An Overview of Energy Metabolism and Alternatives for Targeted Cancer Therapy. <i>Current Medicinal Chemistry</i> , 2021, 28, 3514-3534.	2.4	4
4	Epidermal growth factor receptor regulates fibrinolytic pathway elements in cervical cancer: functional and prognostic implications. <i>Brazilian Journal of Medical and Biological Research</i> , 2021, 54, e10754.	1.5	2
5	Precision Medicine: Technological Impact into Breast Cancer Diagnosis, Treatment and Decision Making. <i>Journal of Personalized Medicine</i> , 2021, 11, 1348.	2.5	5
6	Positive crosstalk between EGFR and the TF-PAR2 pathway mediates resistance to cisplatin and poor survival in cervical cancer. <i>Oncotarget</i> , 2018, 9, 30594-30609.	1.8	37
7	The Challenge of Translating System Biology into Targeted Therapy of Cancer. <i>Computational Biology</i> , 2018, , 175-194.	0.2	1
8	Ion Channel and Neurotransmitter Modulators as Electroceutical Approaches to the Control of Cancer. <i>Current Pharmaceutical Design</i> , 2017, 23, 4827-4841.	1.9	32
9	Chemical synthesis, pharmacological evaluation and in silico analysis of new 2,3,3a,4,5,6-hexahydrocyclopenta[c]pyrazole derivatives as potential anti-mitotic agents. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 3855-3861.	2.2	8
10	A strategy to identify housekeeping genes suitable for analysis in breast cancer diseases. <i>BMC Genomics</i> , 2016, 17, 639.	2.8	47
11	Antitumor Activity of Lankacidin Group Antibiotics Is Due to Microtubule Stabilization via a Paclitaxel-like Mechanism. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 9532-9540.	6.4	23
12	Toward precision medicine of breast cancer. <i>Theoretical Biology and Medical Modelling</i> , 2016, 13, 7.	2.1	48
13	Osteopontin splice variants expression is involved on docetaxel resistance in PC3 prostate cancer cells. <i>Tumor Biology</i> , 2016, 37, 2655-2663.	1.8	27
14	Validation of a network-based strategy for the optimization of combinatorial target selection in breast cancer therapy: siRNA knockdown of network targets in MDA-MB-231 cells as an <i>in vitro</i> model for inhibition of tumor development. <i>Oncotarget</i> , 2016, 7, 63189-63203.	1.8	49
15	Optimization of combination chemotherapy based on the calculation of network entropy for protein-protein interactions in breast cancer cell lines. <i>EPJ Nonlinear Biomedical Physics</i> , 2015, 3, .	0.8	22
16	A Computational Strategy to Select Optimized Protein Targets for Drug Development toward the Control of Cancer Diseases. <i>PLoS ONE</i> , 2015, 10, e0115054.	2.5	40
17	Osteopontin-c mediates the upregulation of androgen responsive genes in LNCaP cells through PI3K/Akt and androgen receptor signaling. <i>Oncology Letters</i> , 2015, 9, 1845-1850.	1.8	8
18	Changes in the transcriptional profile in response to overexpression of the osteopontin-c splice isoform in ovarian (OvCar-3) and prostate (PC-3) cancer cell lines. <i>BMC Cancer</i> , 2014, 14, 433.	2.6	22

#	ARTICLE	IF	CITATIONS
19	Abstract 1346: Osteopontin-b and Osteopontin-c splicing isoforms activate prostate cancer cells prosurvival features. , 2014, , .		0
20	Human osteopontin splicing isoforms: Known roles, potential clinical applications and activated signaling pathways. Cancer Letters, 2013, 331, 11-17.	7.2	101
21	Abstract B78: Osteopontin-c splicing isoform is a key molecule in ovarian cancer progression. , 2013, , .		0
22	Both osteopontinâ€c and osteopontinâ€b splicing isoforms exert proâ€tumorogenic roles in prostate cancer cells. Prostate, 2012, 72, 1688-1699.	2.3	48
23	Expression analysis of osteopontin mRNA splice variants in prostate cancer and benign prostatic hyperplasia. Experimental and Molecular Pathology, 2012, 92, 13-19.	2.1	38
24	Abstract 89: Osteopontin-c and osteopontin-b splicing isoforms activate prostate cancer progression features. , 2012, , .		2
25	Osteopontin is a tumor autoantigen in prostate cancer patients. Oncology Letters, 2011, 2, 109-114.	1.8	10
26	Osteopontin-c Splicing Isoform Contributes to Ovarian Cancer Progression. Molecular Cancer Research, 2011, 9, 280-293.	3.4	81
27	Abstract 5256: Osteopontin-c and Osteopontin-b splicing isoforms activate important hallmarks of cancer contributing to prostate carcinoma progression. , 2011, , .		0
28	Abstract 1194: The splicing isoform osteopontin-c contributes to ovarian cancer progression. , 2010, , .		0
29	Analysis of Inherited Genetic Variants in ret Proto-Oncogene of Brazilian Patients with Apparently Sporadic Medullary Thyroid Carcinoma. Thyroid, 2006, 16, 9-15.	4.5	7